Access to Antiobesity Medications Is Still Lacking
An analysis presented at the AMCP 2025 Annual Meeting found that, on average, less than one-third of commercial members currently have coverage for antiobesity...
Delandistrogene Moxeparvovec for DMD Not Associated With Cardiac Effects
One year after treatment with the gene therapy delandistrogene moxeparvovec for Duchenne muscular dystrophy (DMD), researchers observed no changes in cardiac function, volume, or...
How Will the IRA’s Maximum Fair Price Requirements Impact the Industry?
The Inflation Reduction Act (IRA) will result in impacts to Medicare Part D formulary design. A session at the AMCP 2025 Annual Meeting explored...
Rapid Pace of New Therapies, High Costs Are Challenges to the Multiple Myeloma Treatment...
Multiple myeloma (MM) accounts for 1.8% of all new cancers in the United States but is typically in the top 3 cancers for payer...